Tue, July 21, 2020 2:00PM - 3:00PM EDT
This interactive live webinar is part 2 of the Emerging and Evolving Biomarkers Series.
Description:
Homologous recombination deficiency score (HRD) includes assessment of loss of heterozygosity, large-scale state transitions, and telomeric allelic imbalance as an assessment of functional loss of homologous recombination repair. HRD score has been studied in multiple tumor types with the aim of predicting therapeutic response independent of homologous recombination repair gene mutation status. The scientific background, testing considerations, and clinical implications will be discussed in this presentation.
Learning Objectives:
1. Describe the biological principles that underlie the relevance of HRD score, including the cellular signaling pathways and cellular processes involved.
2. Discuss the appropriate technical approaches and platforms for HRD score molecular diagnostic testing.
3. Outline the strengths and limitations of described testing approaches.
4. Apply HRD score information so as to order appropriate testing and interpret test results within a clinical context.  |  |
| Speaker: Melinda Telli, MD | Moderator: Kurt Davies, PhD |
|---|
Level of Instruction: Basic
How to Register:
- Click the "Register Now" Button
- Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account by clicking here.
- Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.
This program has been supported through an educational grant from Bristol-Myers Squibb.
.jpg){kind=small}
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Continuing Education Credit Information
CME credit: 1.0CMLE credit: 1.0
Last day to claim credit: August 20, 2020
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This
activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education through the joint providership of American Society
for Clinical Pathology (ASCP) and Association for Molecular Pathology
(AMP). The American Society for Clinical Pathology (ASCP) is accredited
by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours
of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP
Board of Certification (BOC) Certification Maintenance Program
(CMP). CMLE credit hours meet the continuing education requirements for
the ASCP Board of Certification Credential Maintenance Program (CMP) and
state relicensure requirements for laboratory personnel. Participants
should claim only the credit commensurate with the extent of their
participation in the activity.
*Please note: SAM credit is NOT available for this webinar
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation
